Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of Oncology and Medicine, Georgetown University School of Medicine, discusses the ideal therapy for melanoma in the adjuvant setting.
While therapeutic advancements have improved outcomes, metastatic melanoma remains challenging to treat. This study aims to systematically review systemic treatment options for advanced melanoma, focusing on efficacy and safety in the first-line setting. Through a comprehensive search and meta-analysis of ...
According to the National Cancer Institute’s Surveillance Epidemiology and End Results data, melanoma of the skin was estimated to be the cause of death in almost 10,000 people in 2012.1 Unfortunately, melanoma incidence has been on the rise in the United States since 1981, with annual increa...
Rigvir’s approval in Latvia for melanoma treatment signified the global reach of cancer advancements. The successful application of CAR-T cell therapy by Carl June in 2011 and the FDA approval of Pembrolizumab and Nivolumab in 2014 for melanoma treatment highlighted the potential of immunotherapy. P...
The global incidence of melanoma, the most lethal form of skin cancer, continues to escalate, emphasizing the urgent need for more effective therapeutic strategies. This review assesses the latest advancements in topical and transdermal drug delivery systems, positioning them as promising alternatives. ...
Melanoma Prevention, Detection, and Treatment 2024 pdf epub mobi 电子书 著者简介 Melanoma Prevention, Detection, and Treatment 电子书 图书目录 facebooklinkedinmastodonmessengerpinterestreddittelegramtwittervibervkontaktewhatsapp复制链接 想要找书就要到本本书屋 ...
View moretreatment options Treating melanoma Major advances have been made in the treatment of melanoma. Surgery is the initial treatment for melanoma that appears in just one spot. The doctor removes the visible tumor along with 1 to 2.5 centimeters of healthy skin around the tumor, depending on...
BRAF inhibitors have proven clinical activity inBRAF-mutant patients in other tumour locations, such as melanoma, but resistance emerges frequently due to a multitude of escape mechanisms, thereby necessitating combination treatment (Fig.1b). For instance, in vitro studies have suggested that BRAF inh...
Although each of the agents approved for melanoma in 2011 has a unique and specific indication, the FDA approvals of Yervoy (ipilimumab), Sylatron (peginterferon alfa-2b), and Zelboraf (vemurafenib) represent needed additional options in the treatment of melanoma. Yervoy (ipilimumab)1,9,10 On...
(PD-1), have improved overall survival in patients with late-stage melanoma, and biomarker research for personalized therapy is ongoing for each of these treatment modalities. In this review, we will discuss current first-line treatment options, discuss biomarkers supporting treatment decisions, and ...